Affordable Access

deepdyve-link
Publisher Website

Nanoparticle systems for cancer vaccine

Authors
  • Wen, Ru1, 1
  • Umeano, Afoma C2, 2
  • Kou, Yi3, 3
  • Xu, Jian4, 4
  • Farooqi, Ammad Ahmad5, 5
  • 1 Department of Chemistry, University of Georgia, Athens, GA 30602, USA
  • 2 Department of Molecular & Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
  • 3 Department of Molecular & Computational Biology, University of Southern California, Los Angeles, CA 90089, USA
  • 4 Laboratory of Cancer Biology & Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
  • 5 Pakistan
Type
Published Article
Journal
Nanomedicine
Publisher
Future Medicine
Publication Date
Feb 26, 2019
Volume
14
Issue
5
Pages
627–648
Identifiers
DOI: 10.2217/nnm-2018-0147
PMID: 30806568
PMCID: PMC6439506
Source
PubMed Central
Keywords
License
Unknown

Abstract

As effective tools for public health, vaccines prevent disease by priming the body's adaptive and innate immune responses against an infection. Due to advances in understanding cancers and their relationship with the immune system, there is a growing interest in priming host immune defenses for a targeted and complete antitumor response. Nanoparticle systems have shown to be promising tools for effective antigen delivery as vaccines and/or for potentiating immune response as adjuvants. Here, we highlight relevant physiological processes involved in vaccine delivery, review recent advances in the use of nanoparticle systems for vaccines and discuss pertinent challenges to viably translate nanoparticle-based vaccines and adjuvants for public use.

Report this publication

Statistics

Seen <100 times